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Abstract
Background: To test the hypothesis of down-regulating the increased immune system activation/
destruction process associated with chronic HIV infection, we focused our interest on
prednisolone (PDN), because we had showed that, in vitro, PDN had a strong anti-apoptotic activity
on activated T cells of HIV-infected patients and no effect on viral replication. We thus designed in
1992 a pilot study to evaluate the clinical, immunologic and virologic effects of PDN. The drug was
given to a group of 44 patients with CD4 T cells over 200/µl. After one year, no patient had
developed clinical AIDS and the mean CD4 T cell count of the group had increased from 441 ± 21
cells/µl to 553 ± 43 cells/µl. Moreover, markers of immune activation had dropped back to normal
levels while the mean viral load of the group had remained unchanged. Here we explore the long-
term clinical, immunologic, and virologic impact of prednisolone on the chronic phase of HIV
infection.
Methods: Retrospective study over 10 years starting between July 1992 and February 1993. A
total of 44 patients with CD4 cells/µl ranging from 207 to 775 were treated with prednisolone, 0.5
mg/kg/d, over 6 months and 0.3 mg/kg/d thereafter.
Results: No clinical AIDS developed under prednisolone; side effects of the drug were mild. CD4
cells which increased from 421 cells/µl at entry to 625 cells/µl at day 15, slowly decreased to reach
426 cells/µl after two years; T cell apoptosis and activation markers dropped within 15 days to
normal levels and reincreased slowly thereafter. Serum viral loads remained stable. The percentage
of patients maintaining CD4 cells over entry was 43.2% at two years, 11.4% at five years and 4.6%
at 10 years. Initial viral load was highly predictive of the rate of CD4 decrease under prednisolone.
Conclusions: Prednisolone postponed CD4 cell decrease in a viral load dependent manner for a
median of two years and for up to 10 years in a fraction of the patients with a low viral load. These
findings might stimulate clinical trials as well as biological research on the role of antiapoptotic
drugs in HIV infection.
Background
The human immunodeficiency virus type 1 (HIV) is a ret-
rovirus which preferentially infects an important class of
immune cells governing the immune system, the lym-
phocytes of the CD4+ phenotype. HIV infection leads to a
complex immunologic disorder combining a progressive
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B cells, associated with increased serum concentrations of
β2 microglobulin and other immune activation markers.
After three to 20 years of CD4 T cell depletion and
immune activation, which are generally clinically asymp-
tomatic, the CD4 T cell pool eventually collapses and the
various clinical manifestations of AIDS develop.
These observations (most of which were available in the
middle of the 1980s) led us to be interested in immuno-
suppressive compounds as potential treatments of the
chronic phase of HIV infection and tools to better under-
stand its pathogenesis [1]. In September 1985 we thus
started giving Cyclosporin A (CSA) for a year to a group of
27 patients with 300–600 CD4 cells/µl [2]. Long-term fol-
low-up of these patients showed that their mean CD4 cell
count remained stable under CSA while it decreased after
CSA withdrawal [3]. In 1992, we were still thinking that it
was reasonable to test the hypothesis of pharmacologi-
cally down-regulating the increased activity of immune
cells with the objective to slow down the HIV-induced
immune system activation/destruction process. We
focused our interest on prednisolone (PDN), an inexpen-
sive drug belonging to the family of glucocorticoids
(GCs), because we had showed that, in vitro, PDN had a
strong anti-apoptotic activity on activated T cells of HIV-
infected patients and no effect on viral replication [4]. We
thus designed a pilot study to evaluate the clinical, immu-
nologic and virologic effects of PDN. The drug was given
to a group of 44 HIV-infected patients with CD4 T cells
over 200/µl. After one year, no patient had developed
clinical AIDS and the mean CD4 T cell count of the group
had increased from 441 ± 21 cells/µl to 553 ± 43 cells/µl.
Moreover, markers of immune activation had dropped
back to normal levels while the mean viral load of the
group had remained unchanged [5]. At completion of this
one-year study, patients were offered to remain under
PDN for a second year. From the third year, with the con-
currence of the patients, we decided to maintain PDN as
long as the patients' CD4 T cells remained above entry lev-




Patient characteristics have already been described in
detail elsewhere [5]. Briefly, 44 patients (36 men, eight
women, mean age 36 years, 11 under zidovudine, 500
mg/day), a CD4 cell count ranging from 207 to 775 cells/
µl (mean ± SE: 421 ± 21, median 438), no clinical AIDS,
and no GC contra-indications entered in the pilot study
between 1 July 1992 and 19 February 1993. All of them
signed an informed consent before starting PDN. Among
the 44 patients entered in the study, 25 had already been
followed in our institution over the two preceding years
with CD4 cell counts performed at least every six months
and their serum frozen every year.
Oral PDN (Solupred, Laboratoire Houdé, Puteaux,
France) was given at a daily dose of 0.5 mg/kg during the
first six months and at 0.3 mg/kg thereafter. Once they
had completed one year of PDN, patients were offered to
stay under PDN, 0.3 mg/kg/day, for a second year. From
the third to the tenth year, patients whose CD4 T cells
remained over entry level were allowed to remain under
PDN while the others were discouraged to pursue PDN.
Patients who stopped PDN were recommended to
decrease its dose over one to three months; they were also
asked to start antiretroviral therapy (one or two reverse
transcriptase inhibition (RTIs) until April 1996, or an
association of two RTIs and one protease inhibitor (PI)
after this date). Daily potassium and, from the second
year on, calcium and vitamin D tablets as well as a low
sodium diet were recommended to all patients as long as
PDN was taken. Moreover, P. carinii prophylaxis by sul-
famethoxazole and trimethoprim was administered to all
patients during the first year.
Evaluation of the 44 patients entered in the pilot study
was carried out in the three days preceding PDN onset
(day 0), at two weeks, 11 weeks, four months and every
other month during the first year. During the second year,
evaluations were also performed every two months and
from the third year, every three months. Clinical evalua-
tion included measurements of weight and blood pres-
sure as well as research of signs of hypercorticism.
Biological evaluation comprised blood count with CD4+
and CD8+ T lymphocyte phenotypes, glycemia and
plasma K+ concentration. A quantity of 4 ml of serum was
also frozen at each of the above-mentioned time points
for β2 microglobulin and viral load measurements. Dur-
ing the first year, percentages of CD25+ and DR+ pheno-
types in CD4+ T lymphocytes were measured in fresh
samples while the percentage of apoptotic cells in periph-
eral blood mononuclear cells (PBMC) was assessed in fro-
zen samples after overnight culture in the presence of anti-
CD3 monoclonal antibodies (0.5 µg/ml, Becton Dickin-
son) by a flow cytometry-based labelling technique [6].
Control group
With the aim of comparing the evolution of our PDN-
treated group with that of a group representative of the
natural history of HIV infection, 74 HIV-infected individ-
uals were identified from our computerized files through
the four following criteria: 1) first visit to our institution
between January 1987 and March 1993; 2) 200 to 800
CD4 cells/µl, no clinical AIDS and no antiviral therapy at
first visit; 3) a CD4 cell count at least every six (±2)
months over the two subsequent years (or to death if it
occurred within this delay); and 4) a sample of serumPage 2 of 10
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measurements. Over the first two years of observation, 37
of these 74 patients did not receive any anti-viral therapy,
while the other 37 started zidovudine one to 23 months
after their first visit to our institution (median six
months). From the third year of observation on, all
patients who conserved their CD4 T cells over entry levels
were regularly followed at least until their CD4 T cells
decreased to under such levels.
Viral load measurements
Serum viral loads were measured with a quantitative RT-
PCR assay, which was developed and validated in our lab-
oratory [7]. In order to show the impact of initial viral
load on the clinical outcome as well as on the evolution
of biological parameters, we identified the median viral
load value of the 44 patients at PDN onset. Out of the 44
patients entered in the study, 22 had a viral load over
30,000 copies/ml (that is, 4.25 log10 copies/ml) while the
22 others had a viral load under 4.25 log10 copies/ml.
PDN-treated patients with >4.25 log10 copies/ml were
included in the high viral load (HVL) subgroup and those
with <4.25 log10 copies/ml in the low viral load (LVL) sub-
group. Patients of the control group were also divided in
HVL and LVL subgroups according to the same cut-off
value (< or >4.25 log10 copies/ml).
Statistics
All mean values were given with their standard error (SE).
Hematological, immunologic and virologic measures
were compared in the same patients at entry and at differ-
ent time points by the Wilcoxon matched paired single
rank test (Wt). The Mann-Whitney test (MWt) was used to
compare viral loads and CD4 cell counts of different
groups at the same time points. Kaplan Meier analysis was
used to evaluate the percentage of patients of different
groups who remained AIDS-free or the percentage of
patients who maintained their CD4 T cell count above
entry levels for a long time; the log-rank test (LRt) was




The 44 patients entered in the study received 0.5 mg/kg/
day of PDN for six months; PDN was then decreased to
0.3 mg/kg/day. During the first year, five patients decided
to stop taking PDN, two because their CD4 cell count had
dropped under 200 cells/µl and the other three when their
CD4 cells had decreased to less than entry levels; one of
them declined further follow-up at our institution at
month eight. Of the 11 patients who were taking Zidovu-
dine at the time of starting PDN therapy, five decided to
discontinue it at month six. Overall, a total of 39 patients
completed the first year of PDN therapy. During the sec-
ond year, six patients stopped PDN because their CD4
cells had dropped under 200 cells/µl. Thus, after 24
months, a total of 33 patients were still under PDN and
43/44 were available for evaluation. Of note is the fact
that the six patients who were still under Zidovudine
when starting their second year of PDN discontinued their
antiviral treatment between months 13 and 18.
Side effects of PDN were mild. Three patients interrupted
PDN transiently. Moderate enlargement of the face devel-
oped in two patients and a beginning of buffalo neck
appeared in one patient during the second year of treat-
ment. Mean weight increased from 66.4 kg at entry to 67.3
kg at two years (PWt < 0.05). Mean blood pressure slightly
increased from 128/83 mm Hg at entry to 129/84 mm Hg
at two years (PWt = NS) while glycemia and plasma potas-
sium K+ levels remained unchanged.
Lymphadenopathies, which existed in 20 patients at PDN
onset disappeared in 16 after one year and in a total of 19
after two years of therapy. Mild oral thrush which existed
initially in three patients (all of them with a HVL) devel-
oped in 11 others (three with LVL and eight with HVL)
who received short courses of antifungal therapy. Clinical
AIDS (dementia, cachexia and cerebral toxoplasmosis)
developed in three patients 14, 20 and 22 months after
PDN onset. At the time of clinical AIDS, they had 101, 24
and 3 CD4 T cells/µl, were off PDN therapy for eight, eight
and 16 months respectively and two of them were already
receiving RTIs. At PDN onset, these three patients had a
HVL and 256, 337 and 361 CD4 T cells/µl respectively.
Among the 74 patients of the control group, mild immu-
nodeficiency symptoms were not recorded but clinical
AIDS occurred in 11 patients five to 23 months (median
20) after their entry into the control group. At the time
clinical AIDS was diagnosed, all of them had less than 200
CD4 T cells/µl and three were already under RTIs. Initially,
the mean CD4 T cell count of these 11 patients was 428
cells/µl (min 246, max 656, median 440). Seven of them
had an initial HVL while the remaining four had a LVL.
Two-year serum viral loads evolution
Viral loads of PDN-treated and control patients were
almost similar (PMWt = NS at each time points) and
remarkably stable over time: PDN-treated group: entry,
4.1 ± 0.1 log copies/ml; two years, 4.2 ± 0.1 log copies/ml
(PWt = NS); control group: entry 3.8 ± 0.1 log copies/ml;
two years 3.9 ± 0.2 log10 copies/ml (PMWt = NS) (Figure
1A). At entry, viral load levels of LVL and HVL subgroups
were different (PMWt < 0.01). However, the evolution of
the viral load of PDN-treated and control patients with
LVL was almost identical (PMWt = NS each time point) with
a significant increase at two years compared to entry levels
(PWt < 0.01 in both subgroups) (Figure 1B), while entryPage 3 of 10
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BMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/17Evolution of serum viral load and CD4 T cell count in 44 PDN-treated patients and 74 control patientsFigure 1
Evolution of serum viral load and CD4 T cell count in 44 PDN-treated patients and 74 control patients. (A-C), Geometric 
mean ± SE of serum viral load in PDN-treated patients (filled squares) versus control patients (open squares) of total groups 
(A) and subgroups with an initial low viral load (LVL) (B) and high viral load (HVL) (C). (D-F), Mean ± SE of CD4 T cell count 
in PDN-treated patients (filled circles) versus control patients (open circles) of total groups (D) and subgroups with an initial 
LVL (E) and HVL (F).Page 4 of 10
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patients with HVL were similar (PMWt P = NS at each time
points) and remained stable over two years (PWt = NS)
(Figure 1C).
Two-year CD4 T cell count evolution
In the PDN-treated group, the mean entry level of CD4 T
cells was 421 ± 21 cells/µl (median 438). At day 15, CD4
T cell count jumped to 629 ± 39 cell/µl (PWt < 0.01); it
slowly decreased thereafter to reach 426 ± 54 cells/µl after
two years (PWt day 0 – year 2 = NS) (Figure 1D). The evo-
lution of the CD4 T cell counts of the 11 patients who
were under ziduvidine when starting PDN had the same
profile: their CD4 T cells started from lower values (329 ±
35 cells/µl) than those of the entire PDN-treated group;
they also increased at day 15 (490 ± 52 cells/µl) and then
progressively decreased to reach 260 ± 48 cells/µl after two
years.
The CD4 T cell count of the control group started at 427 ±
16 cells/µl at entry (a level almost identical to entry CD4
T cell count of the PDN-treated group). It then decreased
to 282 ± 23 cells/µl after two years of observation (Figure
1D). At each time point (except onset), differences
between PDN-treated and control groups were highly sig-
nificant (PMWt < 0.01).
Two-year impact of initial viral load on CD4 T cell 
evolution
In the PDN-treated group, entry CD4 T cells were 475 ± 30
cells/µl in the 22 patients with a LVL and 366 ± 26 cells/
µl in the 22 patients with a HVL. At day 15, patients of
both subgroups had increased their CD4 T cells (up to 682
± 67/µl in LVL patients, PWt < 0.01, and to 577 ± 41 cells/µl in HVL patients (PWt < 0.05). At month 24, the mean
CD4 T cell count of LVL patients was still 625 ± 81 cells/
µl (PWt day 0 to two years < 0.01, PWt day 15 to two years
= NS, Figure 1E, filled circles). In contrast, the mean CD4
T cell count of HVL patients had dropped to 219 ± 34
cells/µl, a value significantly lower than those of day 0 and
day 15 (PWt < 0.05 Figure 1F, filled circles). Comparison of
HVL and LVL subgroups treated by PDN demonstrate no
significant difference at day 0 (PMWt = NS) or day 15 (PMWt
= NS) but a highly significant difference at each time
points thereafter (PMWt < 0.01).
In control patients, mean CD4 count at entry was 427 ±
19 cells/µl in the 51 patients with a LVL and 428 ± 27
cells/µl in the 23 patients with a HVL. In each subgroup,
CD4 T cells decreased progressively thereafter to reach,
after two years, 333 ± 26 cells/µl in LVL patients (PWt entry
to two years < 0.01) and 168 ± 36 cells/µl in HVL patients
(PWt entry to two years < 0.01 Figure 1E,1F, open circles).
Comparison of HVL and LVL control subgroups demon-
strated no difference at day 0 but a highly significant dif-
ference at each time point (6, 12, 18 and 24 months)
thereafter (PMWt < 0.01).
The comparative evaluation of PDN-treated and control
patients with LVL showed that entry CD4 T cells of the 22
PDN-treated and the 51 control patients were not signifi-
cantly different (PMWt = NS). However, because of the
large increase observed from day 15 in PDN-treated
patients, the difference between the two LVL subgroups
was significantly different at each time point (6, 12, 18
and 24 months) thereafter (PMWt < 0.05) while the slopes
of both curves were almost parallel (from day 15) (Figure
1E).
In HVL subgroups (22 PDN-treated and 23 control
patients), entry CD4 T cells were similar (PMWt = NS).
However the CD4 T cell increase observed at day 15 in
PDN-treated patients was only transient and there was no
difference between the two curves at each time point (6,
12, 18, 24 months) thereafter (PMWt = NS, Figure 1F).
Two-year evolution of total lymphocytes of the PDN-
treated group
The total lymphocytes count followed the same profile as
that of the CD4 T cells count (Figure 2) while CD8 T cells
remained almost stable (PMWt day 0 to two years = NS)
and not significantly different (PWt = NS at each time
point) in the LVL and HVL PDN-treated subgroups (data
not shown).
Evolution of total lymphocyte count in PDN-treated patientsFigure 2
Evolution of total lymphocyte count in PDN-treated patients. 
Mean ± SE of lymphocyte count in total group (filled circles) 
and subgroups with an initial LVL (down-pointing triangles) 
and HVL (up-pointing triangles).Page 5 of 10
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PDN-treated patients
The percentage of apoptotic cells in PBMC started from 21
± 10%; it substantially decreased to 15 ± 9% at day 15 (PWt
< 0.01) and remained decreased at one year (14 ± 5%,
(PWt day 0 to one year) (Figure 3A). The percentage of
CD25+ and DR+ phenotypes in CD4 cells followed almost
the same profile; it started from 17 ± 3% at day 0, and then
decreased to 14 ± 1% at day 15 (PWt = NS), 12 ± 1% at
month 4 (PWt < 0.03) and 9 ± 1% at one year (PWt < 0.01)
(Figure 3B). Finally, the percentage of DR+ cells started
from 20 ± 2% at day 0, decreased to 17 ± 2% at day 15
(PWt = NS), 13 ± 1% at month 4 (PWt < 0.01) and remained
significantly decreased at one year (18 ± 3, PWt < 0.05)
(Figure 3C).
β2 microglobulin levels also decreased in PDN-treated
patients from 3.6 ± 0.2 mg/l at day 0, to 3 ± 0.2 mg/l at
day 15 (PWt < 0.01) and 2.5 ± 0.2 mg/l at month 6 (PWt <
0.01); β2 microglobulin concentration then slowly
reincreased thereafter but remained significantly lower
than that of entry: 3.1 ± 0.3 mg/l at month 12, (PWt <
Evolution of the percentage of apoptotic cells in PBMC, CD25+ and DR+ cells in CD4 T cells, and serum β2-microglobulin in PDN-treated patientsFigure 3
Evolution of the percentage of apoptotic cells in PBMC, CD25+ and DR+ cells in CD4 T cells, and serum β2-microglobulin in 
PDN-treated patients. Mean ± SD of the percentage of apoptotic cells in PBMC (A), CD25+ cells in CD4 T cells (B), DR+ cells 
in CD4 T cells (C) and β2-microglobulin (D) in subgroups with an initial LVL (down-pointing triangles) and HVL (up-pointing 
triangles).Page 6 of 10
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0.4 mg/l at year 2 (PWt < 0.05) (Figure 3D).
At entry, the above-mentioned markers were significantly
different in LVL and HVL subgroups (percentage of apop-
totic cells in PBMC, PMWt < 0.01; percentages of CD25+
and DR+ cells in CD4 T cells, PMWt < 0.01; serum β2
microglobulin, PMWt = 0.03) and these values remained
significantly different (PWt < 0.05 until month 12 for all
cellular markers and until month 18 for β2 microglobulin
(Figures 3A,3B,3C,3D).
Two-year probabilities of AIDS
Among the 44 patients of the PDN-treated group, CD4 T
cell counts decreased to less than 200 cells/µl (a level
which defines AIDS) in nine patients including the three
patients who developed clinical AIDS. These nine patients
belonged to the subgroup of 22 patients with HVL. Two-
year AIDS free rates were thus very different in the LVL
subgroup (100%) and the HVL subgroup (59.1 ± 10%,
PLRt < 0.01).
Among the 74 patients of the control group, CD4 T cells
of 31 patients decreased to less than 200 cells/µl, of whom
11 patients developed clinical AIDS. Among these 31
patients, 16 belonged to the subgroup of 23 patients with
HVL while the remaining 15 belonged to the subgroup of
51 patients with LVL. Two-year AIDS free rates were thus
70.1 ± 6% for the LVL subgroup versus 30.4 ± .9% for the
HVL subgroup (PLRt < 0.01).
Comparison of PDN-treated and control patients showed
that by two years, 79.5 ± 6% of the PDN-treated patients
remained AIDS-free versus 57.6 ± 6% of the control group
(PLRt = 0.02). All patients (100%) of the PDN-treated sub-
group with LVL remained AIDS-free versus 70 ± 6% of the
LVL control subgroup (PLRt < 0.01); in contrast, AIDS-free
rates were only 59.1 ± 10% for the HVL PDN-treated
patients and 30.4 ± 9% for the HVL control patients (PLRt
= NS).
CD4 T cell counts and viral load levels before and under 
prednisolone
Among the 44 patients who started PDN, 25 were already
followed in our institution during the two years preceding
PDN onset (as already mentioned in Methods). During
this two-year period, the mean CD4 T cell count of these
25 patients decreased from 688 ± 57 cells/µl (month -24)
to 409 ± 28 cells/µl (PDN onset). Once under PDN the
mean CD4 T cell count of these 25 patients followed the
same profile (603 ± 53 cell/µl at day 15 and 387 ± 57
cells/µl at month 24, Figure 4) as that of the entire PDN-
treated group. Mean viral load of these 25 patients
remained stable whether they were off PDN or on PDN (-
24 months: 4.13 ± 0.14 log copies/ml, PDN onset: 4.11 ±
0.12 log copies/ml, +24 months 4.17 ± 0.13 log copies/
ml), PWt = NS at each time point).
Ten-year results of prednisolone treatment
From the third year, PDN was maintained only in the
patients whose CD4 T cells remained over entry levels and
no patient, whether belonging to the PDN-treated or to
the control group, developed clinical AIDS or started any
antiretroviral therapy while having CD4 T cells over entry
levels. The long-term impact of PDN on the evolution of
HIV-infection was therefore evaluated by measuring the
Kaplan-Meier percentage of patients maintaining their
CD4 T cell count above entry for a long time (since all
patients were receiving PDN at least until such CD4 T cell
levels). The percentage of patients of the control group
maintaining their CD4 T cell count over baseline was also
calculated. By two years, 43.2 ± 7.5% of the PDN group
maintained their CD4 T cell count over entry; by five
years, 11.4 ± 4.8% had still increased CD4 T cell counts
(Figure 4). Finally, by ten years (30 March 2003), two
patients (4.6 ± 2%) were still under PDN with CD4 cell
counts over entry. In contrast, in the control group, per-
centages of patients with CD4 T cells remaining over entry
were 12.2 ± 3.1%, 1.3 ± 1.3% and 0% at two, five and ten
years respectively (PLRt < 0.01) (Figure 5A).
The impact of initial viral load on the percentage of
patients maintaining their CD4 T cells over baseline was
strong. By two, five and ten years, 72.7 ± 9.5%, 22.7 ±
8.9% and 9.1 ± 4% of the PDN-treated patients with LVL
Evolution of CD4 T cell counts in 24 patients before and under prednisoloneFigu e 4
Evolution of CD4 T cell counts in 24 patients before and 
under prednisolone. Mean ± SE of CD4 T cell counts before 
(open circles) and under prednisolone (filled circles).Page 7 of 10
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7.3% 0% and 0% of those with HVL (PLRt < 0.01).
In control patients, by two, five and ten years, 15.7 ±
5.1%, 2 ± 2% and 0% of the LVL subgroup maintained
their CD4 T cells versus 4.3 ± 4.2%, 0% and 0% in the HVL
subgroup (PLRt = 0.01). In patients with LVL the ten-year
percentage of patients with no CD4 cell decrease was
higher in PDN-treated patients (9.1%) than in control
patients (0%, PLRt < 0.01, Figure 5B).
In contrast, in patients with HVL the percentage of
patients maintaining their CD4 T cells over entry was only
significantly increased for up to two years in PDN-treated
patients (13.6%) compared to control patients (0%) (P <
0.05) (Figure 5C).
Discussion
Prednisolone, an immunosuppressive drug belonging to
the GC family was given at moderate doses to 44 HIV-
infected patients with CD4 T cells ranging from 207 to
775 cells/µl. Side effects were mild; no patient on PDN or
after PDN withdrawal developed symptoms of hip
necrosis, the fear of which was the cause of the premature
arrest at eight weeks of a double-blind trial testing pred-
nisone versus a placebo [8].
The marked increase in the CD4 cell count observed in
PDN-treated patients at day 15 was in striking contrast
with the well-known GC-induced CD4 T lymphopenia
observed in normal subjects [9]. Importantly, this CD4 T
cell increase occurred without any modification of the
viral load. Moreover, it was associated with a symmetric
decrease in the serum β2-microglobulin concentration,
the percentage of apoptotic peripheral blood lymphocytes
and the percentage of CD4 T cells bearing DR+ or CD25+
markers. It is reasonable to suspect that these
modifications are representative of the inhibition of the
abnormal activation-induced T cell apoptosis in lym-
phoid tissues proper to the chronic phase of HIV
infection. Moreover it is also conceivable that GCs could
delay or even stop CD4 T cell homing and apoptosis in
lymph nodes by down-regulating L-selectin on peripheral
lymphocytes [10]. The absence of modification of serum
viral load in spite of the strong CD4 cell increase suggests
that the CD4 T cells, which were prevented from dying by
PDN, were not productively infected. This is in keeping
with our in vitro observations showing that PDN did not
modify HIV replication but antagonized activation-
induced apoptosis of non-infected T cells [4]. Altogether,
these results argue against the paradigm assuming that the
CD4 T cell depletion from lymphoid tissues was mainly
due to the cytopathic effect of the virus on CD4 T cells and
to the incapacity of the immune system to replace these
cells in time [11-13]. On the contrary, our results bring
experimental arguments in favor of the concept that HIV-
induced immune activation is at least in part the cause of
the depletion of (non-infected) CD4 T cells [14,15].
Absence of CD4 T cell decrease in PDN-treated and control pati ts over 10 yearsFigure 5
Absence of CD4 T cell decrease in PDN-treated and control 
patients over 10 years. Percentage of patients maintaining 
their CD4 T cells over entry level in PDN-treated patients 
(solid lines) versus control patients (dashed lines) of total 
groups (A) and subgroups with an initial LVL (B) and HVL 
(C).Page 8 of 10
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to be a good surrogate marker of the immunologic evolu-
tion of patients without treatment as well as of those
under highly active anti-retroviral therapy (HAART), it
remains that, in PDN-treated patients, we have no infor-
mation on what happens in the lymphoid tissues which
are the site of both HIV replication, T cell proliferation,
differentiation and apoptosis.
After the initial increase of the CD4 cell count, although
the viral load remained remarkably stable, PDN (at the
dose at which it was given) was probably no longer able
to fight both T cell-activation and apoptosis processes in
the subgroup of patients with a HVL. In contrast, in
patients with a LVL, abnormal HIV-induced T cell activa-
tion and apoptosis were controlled by PDN for up to 10
years in a fraction (9.1%) of the patients (Figure 5B).
The absence of viral load increase under PDN questions
the role of cytotoxic CD8 T lymphocytes in the chronic
phase of HIV infection. Since it has recently been
demonstrated that GCs are capable of inhibiting the dif-
ferentiation of dendritic cells (the most potent antigen-
presenting and T-cell stimulating cells) in vitro [16], it is
conceivable that the number of HIV-specific CD8 T cells
of PDN-treatment patients could be somehow reduced. If
HIV-specific CD8 T cells play a significant role in control-
ling viral replication (via their cytolytic activity toward
productively infected CD4 T cells), an increase in plasma
HIV RNA levels should be expected in patients under PDN
(at least within the first months of PDN-treatment during
which in vivo T-cell reactivity was significantly down-regu-
lated). The present study showed that it was not the case.
It is established that HIV-specific memory CD8 T cells do
exist along the chronic phase of the infection as shown by
HIV peptides HLA tetramers [17] and that they can differ-
entiate in vitro in functional effector cells (that is, capable
of suppressing viral replication in infected CD4 T cells)
following adequate stimulation [18-20]. However in vivo
functional (terminally differentiated) effector CD8 T cells
are lacking in patients with chronic HIV infection [21-23].
This retrospective study obviously does not have the
demonstrative strength of a prospective randomized trial.
However, the 25 patients who were followed in our insti-
tution during the two years preceding PDN onset (internal
control) and the 74 individuals of the control group
(external control) allowed us to draw some firm conclu-
sions at least on CD4 T cells count, the main surrogate
marker of the immune system's progressive destruction
along the course of HIV infection [24], and viral load evo-
lution under PDN. Overall, the progressive CD4 T cell
count decrease proper to the chronic phase of HIV infec-
tion was postponed for two years (Figures 1D and 4). Ini-
tial viral loads were highly predictive of the CD4 T cell
evolution both in the PDN-treated group and the control
group (Figure 1E,1F) and, after two years, AIDS occurred
significantly less frequently in the PDN-treated group
than in the control group (PLR = 0.02). This is particularly
true when comparing PDN-treated and control patients
with LVL (PLRt < 0.01).
Results of this long-term study suggest several types of ran-
domized trials. In developed countries (where HAART
treatments and frequent immuno-virologic measure-
ments are available), GCs should be tried in association
with HAART versus HAART alone in primary infection.
CSA, a more immunosuppressive and more toxic drug
than PDN has recently been given in this setting with suc-
cess [25]. In the chronic phase of the infection, several
doses of PDN or other compounds of the GC family
should be tested versus a placebo in patients without AIDS
and with <30,000 HIV RNA copies/ml in order to define
the best type and the lowest dose of GCs capable of main-
taining CD4 T cell counts over entry (or a predefined
level) without excessive toxicity and without developing
AIDS. The objective of such trials should be to delay the
moment where HAART (with its well-known long-term
side effects) should be started.
In developing countries (where access to antiretroviral
treatments is limited), PDN should be tried versus a pla-
cebo or no treatment in patients without opportunistic
infections. Such studies should only be started after hav-
ing carefully checked the absence of evolutive infections
(such as tuberculosis) susceptible to be worsened by the
long-term use of GCs. In the context of developing coun-
tries, the main entry and endpoint criteria could be the
peripheral blood total lymphocytes count, which was
shown (Figure 3) to be a good surrogate marker of CD4
cell evolution under PDN. A randomized trial measuring
the time during which total lymphocytes remain over
entry (or a pre-defined) level and the percentage of clini-
cal AIDS episodes within this duration would be of use in
evaluating the duration of time during which GCs could
delay the moment where AIDS develops, and/or anti-viral
therapies (if available) should be given.
Conclusions
Prednisolone postponed CD4 cell decrease in a viral load
dependent manner for a median of two years and for up
to 10 years in a fraction of patients with a low viral load.
These findings might stimulate clinical trials as well as
biological research on the role of antiapoptotic drugs in
HIV infection.
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GCs, glucocorticoids; PDN, prednisolone; CSA,
cyclosporine A; HVL, high viral load; LVL, low viral load;
Wt, Wilcoxon matched paired single rank test; Mwt,
Mann-Whitney test; Lrt, log-rank test; HAART, highly
active anti-retroviral therapy.
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